Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4247147 in Participants With Obesity or Overweight
NCT07915245Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4247147 in obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 33 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LY4247147
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07915245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915245.